Abstract
Activation and control of the immune system is regulated by costimulatory molecules as well as by checkpoint inhibitors. Checkpoints are essential in maintaining self-tolerance and minimizing collateral damage by modulating the immune response. Evasion of the immune system, one of the hallmarks of cancer, has been found to include interference with checkpoints by tumor cells as one of the evasive mechanisms. Tumor cells express molecules that when bound to their respective ligand or receptor, send out inhibitory signals that block T-cell activation. Specific antibodies have been engineered against these Immunosuppressive molecules (mainly CTLA-4 and PD-1) such that the T-cells can exert cytotoxic anti-tumor effects. These
Highlights
Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol
Summary of BMT-Specific Adverse Events that may be used if specified by the protocol. These differ from the standard COMMON TOXICITY CRITERIA (CTC) and may be more relevant to the transplant setting
Diarrhea associated with none graft versus host disease (GVHD) for BMT studies
Summary
Note: See the HEMORRHAGE category for grading the severity of bleeding events.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Immunology and Immunotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
